P1103: INMIND: A PHASE 3 STUDY OF TAFASITAMAB PLUS LENALIDOMIDE AND RITUXIMAB VERSUS PLACEBO PLUS LENALIDOMIDE AND RITUXIMAB FOR RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) OR MARGINAL ZONE LYMPHOMA (MZL)
oleh: L. H. Sehn, K. Hübel, S. Luminari, A. Salar, B. E. Wahlin, A. K. Gopal, C. Bonnet, S. Paneesha, M. Trneny, H. Mashegu, C. Lihou, D. Li, C. W. Scholz
| Format: | Article |
|---|---|
| Diterbitkan: | Wiley 2022-06-01 |
Deskripsi
No description available for this item.